Related Experiment Video

Updated: May 27, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Bevacizumab and ovarian cancer

Shinya Sato1, Hiroaki Itamochi

  • 1Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Tottori, Japan.

Current Opinion in Obstetrics & Gynecology
|November 30, 2011
PubMed
Abstract

Insights

Bevacizumab shows promise in treating epithelial ovarian cancer (EOC) by targeting vascular endothelial growth factor (VEGF). While improving progression-free survival, it did not extend overall survival and has associated adverse events requiring further study.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Vascular endothelial growth factor (VEGF) is a key pathway in tumor angiogenesis and is frequently overexpressed in epithelial ovarian cancer (EOC).
  • VEGF is a validated therapeutic target in various cancers, including EOC.

Purpose of the Study:

  • To review the rationale for targeting angiogenic pathways with bevacizumab, an anti-VEGF agent, in epithelial ovarian cancer.
  • To evaluate the efficacy, safety, and cost-effectiveness of bevacizumab in EOC treatment.

Main Methods:

  • Review of phase II and III clinical trials evaluating bevacizumab in EOC.
  • Analysis of response rates, progression-free survival, overall survival, and adverse events.

Main Results:

  • Bevacizumab monotherapy demonstrated response rates of 16-21% in phase II trials.
  • Phase III trials showed bevacizumab plus chemotherapy significantly improved progression-free survival but not overall survival in advanced EOC.
  • Common adverse events include hypertension and proteinuria; bowel perforation risk increased in heavily pretreated patients. Cost-effectiveness remains a concern.

Conclusions:

  • Bevacizumab exhibits significant activity and is a promising agent for EOC.
  • Further understanding of bevacizumab's adverse events and identification of predictive biomarkers are crucial for patient selection.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.